Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Interaction of BR1018-1 and BR1018-2 in Healthy Adults
NCT05460364Phase 1Completed
- Sponsor
- Boryung
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BR1018-1 and BR1018-2 in hypertension (HTN) and hypercholesterolemia (6 arms), sponsored by Boryung. Primary endpoints: Area Under the Concentration-Time Curve from 0 to 24 Hours at Steady State and Maximum Plasma Concentration at Steady State. Started Aug 2022; status: completed.
02
Drugs
BR1018-1BR1018-2
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT05460364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05460364.